Literature DB >> 26648632

Vortioxetine.

.   

Abstract

Entities:  

Year:  2015        PMID： 26648632      PMCID： PMC4653968          DOI： 10.18773/austprescr.2015.037

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  7 in total

1.  A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Ioana Florea
Journal:  J Psychopharmacol       Date:  2012-04-09       Impact factor: 4.153

2.  A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Authors:  Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen
Journal:  Curr Med Res Opin       Date:  2013-01-17       Impact factor: 2.580

3.  A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Authors:  Neven Henigsberg; Atul R Mahableshwarkar; Paula Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2012-07       Impact factor: 4.384

4.  A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

Authors:  Rakesh Jain; Atul R Mahableshwarkar; Paula L Jacobsen; Yinzhong Chen; Michael E Thase
Journal:  Int J Neuropsychopharmacol       Date:  2012-09-11       Impact factor: 5.176

5.  A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.

Authors:  Cornelius Katona; Thomas Hansen; Christina Kurre Olsen
Journal:  Int Clin Psychopharmacol       Date:  2012-07       Impact factor: 1.659

6.  A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.

Authors:  Enric Alvarez; Victor Perez; Marianne Dragheim; Henrik Loft; Francesc Artigas
Journal:  Int J Neuropsychopharmacol       Date:  2011-07-18       Impact factor: 5.176

7.  Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.

Authors:  Jean-Philippe Boulenger; Henrik Loft; Christina Kurre Olsen
Journal:  Int Clin Psychopharmacol       Date:  2014-05       Impact factor: 1.659
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.